JPMorgan Lowers Illumina's Price Target to $120, Maintains Neutral Rating
Feb 09, 2026 16:59
CST Updated
16:59
Illumina
Diagnostic Product Developer
Gelonghui February 9 | JPMorgan downgraded Illumina's target price from $130 to $120, maintaining a "neutral" rating. (Gelonghui)